StreetInsider.com News Articles

Form 4 Oncology Institute, Inc. For: Jul 14 Filed by: Podnos Yale

Thu, 16 Jul 2026 20:06:00 -0400

si-local-file:///var/storage/secattach/20260716/26780948.html

Form 4 Oncology Institute, Inc. For: Jul 14 Filed by: Podnos Yale

Thu, 16 Jul 2026 20:06:00 -0400

si-local-file:///var/storage/secattach/20260716/26780948.html

Topicus.com Inc. Announces Release Date for Second Quarter Results

Thu, 16 Jul 2026 17:37:00 -0400

TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) announced today it intends to release its second quarter results on August 5, 2026.

The Company’s quarterly results will be disseminated via press release and made available on the Company’s website (www.topicus.com) and the SEDAR website (www.sedarplus.ca), after markets close on Wednesday, August 5, 2026.

About Topicus.com Inc.

Topicus’ subordinate voting shares are listed on the Toronto Venture Stock Exchange under the symbol "TOI". Topicus acquires, manages and builds vertical market software businesses.

Topicus.com Inc. Announces Release Date for Second Quarter Results

Thu, 16 Jul 2026 17:37:00 -0400

TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) announced today it intends to release its second quarter results on August 5, 2026.

About Topicus.com Inc.

Topicus’ subordinate voting shares are listed on the Toronto Venture Stock Exchange under the symbol "TOI". Topicus acquires, manages and builds vertical market software businesses.

Topicus.com Inc. Announces Release Date for Second Quarter Results

Thu, 16 Jul 2026 17:37:00 -0400

TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) announced today it intends to release its second quarter results on August 5, 2026.

About Topicus.com Inc.

Topicus’ subordinate voting shares are listed on the Toronto Venture Stock Exchange under the symbol "TOI". Topicus acquires, manages and builds vertical market software businesses.

Topicus.com Inc. Announces Release Date for Second Quarter Results

Thu, 16 Jul 2026 17:37:00 -0400

TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) announced today it intends to release its second quarter results on August 5, 2026.

About Topicus.com Inc.

Topicus’ subordinate voting shares are listed on the Toronto Venture Stock Exchange under the symbol "TOI". Topicus acquires, manages and builds vertical market software businesses.

Form 144 Oncology Institute, Inc. Filed by: Podnos Yale

Tue, 14 Jul 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260714/26768668.html

Form 144 Oncology Institute, Inc. Filed by: Podnos Yale

Tue, 14 Jul 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260714/26768668.html

Form 4 Oncology Institute, Inc. For: Jul 10 Filed by: Chernett Jorey

Mon, 13 Jul 2026 11:34:00 -0400

si-local-file:///var/storage/secattach/20260713/26761400.html

Form 4 Oncology Institute, Inc. For: Jul 10 Filed by: Chernett Jorey

Mon, 13 Jul 2026 11:34:00 -0400

si-local-file:///var/storage/secattach/20260713/26761400.html

Form 4 Oncology Institute, Inc. For: Jul 07 Filed by: STOLPER MARK

Thu, 09 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260709/26753565.html

Form 4 Oncology Institute, Inc. For: Jul 07 Filed by: STOLPER MARK

Thu, 09 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260709/26753565.html

Form 4 Oncology Institute, Inc. For: Jul 07 Filed by: TZOUMAKAS KIMBERLY JO

Thu, 09 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260709/26753568.html

Form 4 Oncology Institute, Inc. For: Jul 07 Filed by: TZOUMAKAS KIMBERLY JO

Thu, 09 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260709/26753568.html

The Oncology Insititute Inc. (TOI) PT Raised to $9 at BTIG

Thu, 09 Jul 2026 12:43:41 -0400

BTIG analyst David Larsen raised the price target on The Oncology Insititute Inc. (NASDAQ: TOI) to $9.00 (from $8.00) while maintaining a Buy rating.

The analyst comments "On Tuesday 7/7/26, TOI announced that it has repaid its outstanding $86M senior secured convertible note with Deerfield Partners, through a debt refinancing that includes a new credit facility from OrbiMed, a global investment firm specializing in healthcare. The transaction helps TOI increase liquidity, improve operating flexibility, and extend debt maturities. Under the new financing arrangement with OrbiMed, TOI repaid the outstanding balance of its $86M senior secured convertible note with Deerfield with a

The Oncology Insititute Inc. (TOI) PT Raised to $9 at BTIG

Thu, 09 Jul 2026 12:43:41 -0400

BTIG analyst David Larsen raised the price target on The Oncology Insititute Inc. (NASDAQ: TOI) to $9.00 (from $8.00) while maintaining a Buy rating.

Form 8-K Oncology Institute, Inc. For: Jul 01

Tue, 07 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260707/26742536.html

Form 8-K Oncology Institute, Inc. For: Jul 01

Tue, 07 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260707/26742536.html

The Oncology Institute repays $86M note via OrbiMed refinancing

Tue, 07 Jul 2026 09:00:55 -0400

The Oncology Institute, Inc. (NASDAQ: TOI) has repaid its $86 million senior secured convertible note with Deerfield Partners through a debt refinancing with OrbiMed, according to a press release issued July 7, 2026.

Under the new financing arrangement, TOI repaid the outstanding balance using a new $75 million term loan from OrbiMed, maturing in 2031, combined with approximately $11 million in cash from its balance sheet. The company stated no additional equity was raised as part of the transaction.

Daniel Virnich, MD, CEO of TOI, said the transaction "significantly extends debt maturities and establishes committed funding from two leading healthcare financing institutions."

The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity

Tue, 07 Jul 2026 09:00:00 -0400

CERRITOS, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, announced today that it has repaid its $86 Million senior secured convertible note with Deerfield Partners through a debt refinancing that includes new credit facilities from OrbiMed.

This transaction is intended to increase liquidity, improve operating flexibility and extend debt maturities. Under the new financing arrangements with OrbiMed, TOI repaid the outstanding balance of its $86 million senior secured convertible note with a new $75 million term loan with OrbiMed maturing

The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity

Tue, 07 Jul 2026 09:00:00 -0400

The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity

Tue, 07 Jul 2026 09:00:00 -0400

The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity

Tue, 07 Jul 2026 09:00:00 -0400

Lake Street Starts The Oncology Insititute Inc. (TOI) at Buy

Mon, 06 Jul 2026 08:52:18 -0400

(Updated - July 6, 2026 8:52 AM EDT)

Lake Street analyst Ben Haynor initiates coverage on The Oncology Insititute Inc. (NASDAQ: TOI) with a Buy rating and a price target of $10.00.

The analyst comments "Rapidly Rising Oncology Drug Spend Leaves Payors Searching For An Offramp – Anyone paying attention to oncology will have noticed the massive growth in drug spend over the past decade. As an illustrative example, Medicare Part D spending on oral oncolytics advanced from sub-$5B in 2013 to $32B in 2024 – a 20% CAGR. Commercial insurer spend on the oral category advanced just as quickly. With many

Lake Street Starts The Oncology Insititute Inc. (TOI) at Buy

Mon, 06 Jul 2026 08:52:18 -0400

(Updated - July 6, 2026 8:52 AM EDT)

Lake Street analyst Ben Haynor initiates coverage on The Oncology Insititute Inc. (NASDAQ: TOI) with a Buy rating and a price target of $10.00.